Sign up to save your podcasts
Or
Share Cardiology Clinics
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cardiology Clinics
A comprehensive overview of advancements in drug therapies for cardiovascular disease and related conditions, emphasizing the shift toward pharmacologic prevention and management over procedural interventions. The articles discuss new or optimized drug classes aimed at improving patient outcomes, including Angiotensin Receptor Blockers (ARBs) and direct renin inhibitors for the renin-angiotensin-aldosterone system (RAAS), new antiplatelet agents like prasugrel, and anticoagulants for acute coronary syndromes. Furthermore, the texts examine novel strategies for lipid modification, such as CETP inhibitors and extended-release niacin combined with laropiprant to mitigate flushing, and explore the role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors for managing Type 2 Diabetes Mellitus, a major cardiovascular risk factor. Finally, there is an analysis of the cardiovascular risks associated with cyclooxygenase-2 (COX-2) inhibitors (coxibs) in comparison to traditional NSAIDs.
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
View all episodes
By Pharmacy Made SimpleA comprehensive overview of advancements in drug therapies for cardiovascular disease and related conditions, emphasizing the shift toward pharmacologic prevention and management over procedural interventions. The articles discuss new or optimized drug classes aimed at improving patient outcomes, including Angiotensin Receptor Blockers (ARBs) and direct renin inhibitors for the renin-angiotensin-aldosterone system (RAAS), new antiplatelet agents like prasugrel, and anticoagulants for acute coronary syndromes. Furthermore, the texts examine novel strategies for lipid modification, such as CETP inhibitors and extended-release niacin combined with laropiprant to mitigate flushing, and explore the role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors for managing Type 2 Diabetes Mellitus, a major cardiovascular risk factor. Finally, there is an analysis of the cardiovascular risks associated with cyclooxygenase-2 (COX-2) inhibitors (coxibs) in comparison to traditional NSAIDs.
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/
You can listen and download our episodes for free on more than 10 different platforms:
https://linktr.ee/pharmacy_simple
Produced by:
https://www.podcaistudio.com/